Core Insights - Werewolf Therapeutics, Inc. is focused on developing conditionally activated therapeutics to enhance the immune system for cancer treatment and other immune-mediated conditions [1][2] - The company will present data on its IL-2 and IL-12 INDUKINE molecules at the Hanson Wade Cytokine-Based Drug Development Summit, showcasing the validation of its unique immunotherapy approach [2] Company Overview - Werewolf Therapeutics is leveraging its proprietary PREDATOR platform to create therapeutics that stimulate both adaptive and innate immunity, aiming to overcome the limitations of traditional proinflammatory immune therapies [2] - The company's INDUKINE molecules are designed to remain inactive in peripheral tissues and activate selectively within the tumor microenvironment [2] - The most advanced product candidates include WTX-124 and WTX-330, which are conditionally activated IL-2 and IL-12 molecules, respectively, targeting solid tumors and Non-Hodgkin Lymphoma [2] Upcoming Events - Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak at the summit on May 15, 2025, at 4:15 PM ET, discussing the therapeutic index improvements of proinflammatory cytokines for cancer immunotherapy [2]